Five Prime Therapeutics ( NASDAQ:FPRX ) and Relmada Therapeutics ( OTCMKTS:RLMD ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.
Insider and Institutional Ownership
86.0% of Five Prime Therapeutics shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by insiders. Comparatively, 6.1% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and price targets for Five Prime Therapeutics and Relmada Therapeutics, as provided by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Five Prime Therapeutics 0 3 6 0 2.67 Relmada Therapeutics 0 0 0 0 N/A Five Prime Therapeutics currently has a consensus target price of $30.38, suggesting a potential upside of 193.48%. Given Five Prime Therapeutics’ higher probable upside, analysts plainly believe Five Prime Therapeutics is more favorable than Relmada Therapeutics.
Volatility and Risk
Five Prime Therapeutics has a beta of 3.12, indicating that its stock price is 212% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500.
Valuation & Earnings
This table compares Five Prime Therapeutics and Relmada Therapeutics’ revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Five Prime Therapeutics $39.51 million 9.29 -$150.22 million ($5.38) -1.92 Relmada Therapeutics N/A N/A -$8.96 million N/A N/A Relmada Therapeutics has lower revenue, but higher earnings than Five Prime Therapeutics.
This table compares Five Prime Therapeutics and Relmada Therapeutics’ net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Five Prime Therapeutics -221.67% -41.52% -33.92% Relmada Therapeutics N/A N/A -285.12% Summary
Five Prime Therapeutics beats Relmada Therapeutics on 7 of the 10 factors compared between the two stocks.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. Its product candidates also comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor IIb, which is in Phase I clinical trials to treat patients with gastric or gastroesophageal junction and bladder cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 as a monotherapy in various cancers. The company’s FP-1039 is in Phase Ib clinical trials to treat patients with malignant pleural mesothelioma. Its preclinical product candidates include FPA150, a CD8 T cell checkpoint inhibitor antibody; FPA154, a tetravalent agonistic antibody that activates glucocorticoid-induced tumor necrosis factor receptor; and FPT155, a CD80-Fc fusion protein, which modulates signaling pathways. The company has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; collaboration agreement with Roche; and license agreements with bluebird bio, Inc., Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. Five Prime Therapeutics, Inc. was founded in 2001 and is headquartered in South San Francisco, California.
Relmada Therapeutics Company Profile Relmada Therapeutics logo Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
Receive News & Ratings for Five Prime Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Five Prime Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at Contrasting Relmada Therapeutics (RLMD) and Five Prime Therapeutics (FPRX)